Laurie H. Sehn

Laurie Sehn is a Canadian lymphoma expert who contributed to pivotal studies establishing mosunetuzumab, a CD20xCD3 bispecific antibody, as an approved treatment for relapsed/refractory follicular lymphoma. Her research has characterized the clinical activity and safety profile of bispecific antibodies in indolent lymphomas and developed optimal step-up dosing strategies to minimize cytokine release syndrome. She has contributed extensively to NCCN and Canadian lymphoma treatment guidelines. Her work on real-world outcomes in FL complements trial data to guide clinical decision-making.